Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening by Román, R. et al.
Annals of Oncology 23: 104–111, 2012
doi:10.1093/annonc/mdr032
Published online 23 March 2011
Effect of protocol-related variables and women’s
characteristics on the cumulative false-positive risk in
breast cancer screening
R. Roma´n1,2, M. Sala1,2, D. Salas3, N. Ascunce2,4, R. Zubizarreta5 & X. Castells1,2,6* Cumulative
False Positive Risk Group
1Department of Epidemiology and Evaluation, Institut Municipal d’Investigacio´ Me`dica-Parc de Salut Mar Barcelona; 2CIBER de Epidemiologı´a y Salud Pu´blica (CIBERESP),
Barcelona; 3General Directorate of Public Health and Centre for Public Health Research, Valencia; 4Navarra Breast Cancer Screening Programme, Public Health Institute,
CIBERESP, Pamplona; 5Galician Breast Cancer Screening Programme, Public Health and Planning Directorate, Health Office, Santiago de Compostela; 6Department of
Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Auto`noma de Barcelona (UAB), Bellaterra (Barcelona), Spain
Received 23 November 2010; revised 17 January 2011; accepted 19 January 2011
Background: Reducing the false-positive risk in breast cancer screening is important. We examined how the
screening-protocol and women’s characteristics affect the cumulative false-positive risk.
Methods: This is a retrospective cohort study of 1 565 364 women aged 45–69 years who underwent 4 739 498
screening mammograms from 1990 to 2006. Multilevel discrete hazard models were used to estimate the cumulative
false-positive risk over 10 sequential mammograms under different risk scenarios.
Results: The factors affecting the false-positive risk for any procedure and for invasive procedures were double
mammogram reading [odds ratio (OR) = 2.06 and 4.44, respectively], two mammographic views (OR = 0.77 and 1.56,
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respectively), digital mammography (OR = 0.83 for invasive procedures), premenopausal status (OR = 1.31 and 1.22,
respectively), use of hormone replacement therapy (OR = 1.03 and 0.84, respectively), previous invasive procedures
(OR = 1.52 and 2.00, respectively), and a familial history of breast cancer (OR = 1.18 and 1.21, respectively). The
cumulative false-positive risk for women who started screening at age 50–51 was 20.39% [95% confidence interval
(CI) 20.02–20.76], ranging from 51.43% to 7.47% in the highest and lowest risk profiles, respectively. The cumulative
risk for invasive procedures was 1.76% (95% CI 1.66–1.87), ranging from 12.02% to 1.58%.
Conclusions: The cumulative false-positive risk varied widely depending on the factors studied. These findings are
relevant to provide women with accurate information and to improve the effectiveness of screening programs.
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introduction
Reducing the false-positive risk, and therefore its associated
factors, is a major goal of breast cancer screening as it would
improve the balance of benefits and harms of this preventive
modality [1]. The negative effects of false-positive results have
been widely described and include anxiety, additional physician
visits and diagnostic tests, and excision biopsies [2, 3] and may
also affect adherence to subsequent mammographic screening [4].
The benefit of screening is usually measured as mortality
reduction after participation in several screening rounds, while
the false-positive risk is usually assessed for each round, thus
underestimating the cumulative negative effect of participation
in several rounds. Some studies have estimated the cumulative
risk of a false-positive result during a woman’s life span ranging
from 20% to 50% after 10 screening rounds [5–10]. These
estimates were based on different methodologies but the wide
variation observed could also be explained by differences in the
screening setting (opportunistic or population based with
quality standards) and in the cohort of women analyzed.
False-positive recall rates may be affected by screening-
protocol characteristics that are potentially modifiable, such as
double or single mammogram reading [11, 12], the type of
mammography (digital or film-screen) [13] and the number of
images taken [14]. Other factors affecting these rates are women’s
personal characteristics, such as age, use of hormone replacement
therapy (HRT), and a familial history of breast cancer.
A false-positive result leading to an invasive procedure (fine-
needle aspiration, core biopsy, and open biopsy) produces
greater anxiety in women and a higher cost to the health system
than additional imaging tests. The association between false-
positive determinants and whether invasive or noninvasive
procedures are carried out has not been sufficiently evaluated.
This evaluation would provide greater knowledge of breast
cancer screening and its distinguishing features.
The aim of this study was to estimate the cumulative false-
positive risk for all procedures and for invasive procedures
throughout the period of participation in a population-based
breast cancer screening program and to determine the effect of
women’s personal variables and screening-protocol
characteristics on this risk.
methods
setting
All women resident in Spain aged 50–69 are actively invited to participate in
the population-based screening program by written letter every 2 years. A
screening mammogram is offered, allowing women who begin screening at
50–51 years up to a maximum of 10 screening mammograms. Breast cancer
screening in Spain adheres to the European Guidelines for Quality
Assurance in Mammographic Screening [15] and its results meet the
required standards [16, 17]. Each of the 17 administrative regions in Spain
is responsible for the local application of the screening program in its area.
Population-based breast cancer screening in Spain started in 1990 in one
region and became nationwide in 2006. Data from eight regions,
representing 44% of the Spanish target population in 2005, were collected.
The selection criterion for including the regions in the study was
completion of at least three screening rounds by December 2006. Each
region has one or several radiology units that carry out screening. Local
application of the screening program can vary in the target population and
in the mammographic screening protocol used [17].
This study included variables related to the mammographic screening-
protocol and women’s personal characteristics. All information was collected
from each participant at each attendance. The variables related to the
screening protocol included the number of views [one (craniocaudal) or two
(mediolateral oblique and craniocaudal) images were taken for each breast],
reading method (single reading by one radiologist or double reading by two
radiologists, with or without consensus or arbitration), and mammography
type (film-screen or digital). The variables related to women’s personal
characteristics were age, use of HRT at screening or in the previous 6 months,
menopausal status (pre- or postmenopausal), previous invasive procedures
with a benign result, and the presence or absence of a first-degree familial
history of breast cancer. In some regions, however, data on women’s personal
variables were either not routinely gathered or data collection did not meet
the protocol’s requirements before the specified date.
study population
A total of 1 586 762 eligible women participated in at least one screening
round in any of the eight regions from March 1990 to December 2006
(Table 1). These women underwent a total of 4 797 609 screening
mammograms. However, 19 055 women were excluded because their
mammographic screening result was unknown, 2246 because their age at
first screening was not in the 44- to 69-year interval, and 97 because their
age was unknown. The total number of screened women analyzed was
1 565 364, with 4 739 498 mammographic screening tests carried out in 74
distinct radiology units.
definition of a false-positive result
Women with a positive mammographic reading were recalled for further
assessments. A positive mammogram reading was considered a false-positive
result if, after further assessments, breast cancer was not diagnosed.
Additional evaluation to rule out malignancy included both noninvasive
(additional mammography, magnetic resonance imaging, ultrasonography,
etc.) and invasive procedures (fine-needle aspiration cytology, core-needle
biopsy and open surgical biopsy). The diagnostic work-up for further
assessments took place within a maximum of 2 months after screening.
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Women with a negative result (at mammographic reading or after further
assessments) were recalled for a new screening mammography 24 months after
the previous screen. A definitive diagnosis of breast cancer was always
histopathologically confirmed (invasive ductal carcinoma or carcinoma in situ).
Two definitions of false-positive results were used: false-positive results
leading to any procedure (noninvasive and/or invasive further assessments)
and false-positive results leading to invasive procedures (at least one invasive
further assessment was carried out). Screening mammograms repeated due to
insufficient technical quality (<0.2%) were not included as a positive result.
statistical analysis
To calculate the risk of a false-positive result and of cancer detection,
discrete-time hazard models were fitted, as described in detail by Singer and
Willett [18]. This methodology uses a logistic regression approach to
compute these particular survival models with discrete time intervals. Two
sorts of predictors were introduced in the model: ‘time indicators’, given by
the women’s screening round (acting as multiple intercepts), and
‘substantive predictors’ for the effect of covariates on the model. The event
of interest was defined as the occurrence of a first false-positive result.
Subsequent observations were censored in the statistical models to avoid
correlation among repeated participations. As data were collected at each
attendance, time-changing variables could be included in the models.
The models were adjusted by a time period effect (calendar years) as the start
date of the radiology units differed. To improve interpretation of the results of
the regression models in terms of the risks and benefits of screening, the breast
cancer detection model was also included in the tables.
The radiology unit was introduced as a random effect in the models
because of the correlation structure among observations in the same
radiology unit. The GLIMMIX procedure in SAS 9.1 (SAS Institute, Cary,
NC) was used. The models had a multilevel structure component in which
mammographic screenings (level 1) were nested within radiology units
(level 2, random effect). Residual pseudo-likelihood estimation was used in
all the models. Two models were computed to ascertain the effect of
substantive predictors. A full database model with the screening-protocol
variables was computed as this information was always available. The model
was then extended by adding women’s personal variables with the subset of
screening mammograms for which this information was complete. This
subset accounted for 2 777 429 (58.6%) screening mammograms from 45
radiology units. To evaluate possible differences between the initial study
population and the subset with complete information, we compared the
overall false-positive rate and the age distribution among missing and non-
missing data for each personal variable (see supplemental Appendix 1,
available at Annals of Oncology online). Univariate analysis carried out to
evaluate the collinearity of women’s personal variables showed a stable
association of these factors with the false-positive risk.
cumulative risk of a false-positive result
The false-positive risk was projected forward to 10 screening mammograms
for women aged 50–51 years at their first screening round. This 10-
screening projection allowed us to ascertain the risk of a false-positive result
for the entire period women are invited to participate in screening
programs. Projections were carried out assuming that the hazard of the 7th
to 10th mammograms was similar to that of the 6th mammogram.
Mammograms from the 7th to 10th screening were not used for projection
because they represented only 2% of overall screening mammograms and
this information was only available in 12 of the 74 participating radiology
units. From the estimated risk at each screening mammogram obtained
from the regression models, cumulative risk was calculated as the risk for
each screening mammogram multiplied by the proportion of women
without a false-positive result up to that screening; the cumulative risk up
to the previous screening mammogram was then added. Confidence
intervals (CIs) for the cumulative risk of a false positive were calculated
using Greenwood’s approximation [19].
Two extreme risk profiles were defined for projection based on the results
of multivariate analysis. The highest risk profile was defined as a woman
with all the factors associated with an increased false-positive risk. The
lowest risk profile was defined as a woman without any of the factors
corresponding to increased risk.
results
A total of 4 739 498 screening mammograms carried out in
1 565 364 women were analyzed (see Table 1). Of these
participating women, 1 205 943 (77.04%) had a second
Table 1. Screening information description by screening period
1990–1992,
n (%)
1993–1994,
n (%)
1995–1996,
n (%)
1997–1998,
n (%)
1999–2000,
n (%)
2001–2002,
n (%)
2003–2004,
n (%)
2005–2006,
n (%)
Total,
n
Screening tests 67 806 (1.4) 233 407 (4.9) 371 033 (7.8) 485 800 (10.3) 714 981 (15.1) 849 415 (17.9) 932 861 (19.7) 1 084 195 (22.9) 4 739 498
Women screened
(first screening)
61 746 (3.9) 178 245 (11.4) 198 190 (12.7) 198 721 (12.7) 298 747 (19.1) 240 817 (15.4) 196 470 (12.6) 192 428 (12.3) 1 565 364
Screening test
(subsequent
screening)
6060 (0.2) 55 162 (1.7) 172 843 (5.4) 287 079 (9.0) 416 234 (13.1) 608 598 (19.2) 736 391 (23.2) 891 767 (28.1) 3 174 134
Further
assessments
13 037 (3.4) 24 013 (6.4) 35 070 (9.3) 41 886 (11.1) 68 603 (18.1) 64 991 (17.2) 63 945 (16.9) 66 515 (17.6) 378 060
Women with
a FPa
10 175 (3.9) 18 992 (7.2) 27 727 (10.5) 30 077 (11.4) 46 024 (17.5) 43 707 (16.6) 42 278 (16.0) 44 627 (16.9) 263 607
Women with
a FP
(invasive)b
566 (2.3) 2532 (10.4) 2471 (10.1) 3075 (12.6) 4511 (18.5) 4259 (17.4) 3687 (15.1) 3306 (13.5) 24 407
Radiology unitsc 9 21 33 41 63 68 71 74 74
aAn FP result for any procedure (invasive or noninvasive).
bAn FP result for an invasive procedure.
cExpressed as number of radiology units running in that screening period.
FP, false positive.
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screening mammogram, 867 160 (55.40%) had a third and
156 414 (9.99%) a sixth. Mammographic screenings were
carried out by 74 distinct radiology units, with an average of
64 047 screening tests (10th to 90th percentile: 9159–117 988)
and 21 154 women screened per radiology unit (10th to 90th
percentile: 3424–38 268).
Of the 1 565 364 women who participated in at least one
screening round, 467 910 were first screened at 44–49 years,
477 177 at 50–54 years, 300 901 at 55–59 years, 260 223 at 60–64
years, and 59 153 at 65–69 years. Table 2 shows the false-positive
rate for all procedures and for invasive tests and the cancer
detection rate for first and subsequent screening mammograms.
Adjusted odds ratios (ORs) for the false-positive risk for all
procedures, false-positive risk for invasive procedures and the
cancer detection rate related to the screening-protocol variables
are shown in Table 3. Double reading mammograms conferred
a higher risk (OR = 2.06; 95% CI 2.00–2.13) than single reading.
This risk was higher for invasive procedures (OR = 4.44; 95% CI
4.08–4.84). Two mammographic views had a protective effect for
the false-positive risk for all procedures (OR = 0.77; 95% CI
0.76–0.79) but was a risk factor for the false-positive risk for
invasive procedures (OR = 1.56; 95% CI 1.48–1.64). Digital
mammography had a protective effect on the false-positive risk
for invasive procedures (OR = 0.83; 95% CI 0.72–0.96), but this
effect was not statistically significant for the false-positive risk for
all procedures.
The model including the women’s personal variables is
shown in Table 4. A higher risk for the false-positive risk for all
procedures and false-positive risk for invasive procedures was
observed in the youngest women (OR = 1.50; 95% CI 1.46–
1.54 and OR = 1.44; 95% CI 1.30–1.58), women with previous
invasive procedures (OR = 1.52; 95% CI 1.49–1.56 and
OR = 2.00; 95% CI 1.89–2.12), a familial history of breast
cancer (OR = 1.18; 95% CI 1.15–1.20 and OR = 1.21; 95% CI
1.13–1.30) and premenopausal women (OR = 1.31; 95% CI
1.29–1.33 and OR = 1.22; 95% CI 1.16–1.29). HRT conferred
a lower false-positive risk for invasive procedures (OR = 0.84;
95% CI 0.78–0.90).
The overall cumulative risk of a false-positive result for all
procedures and for invasive procedures in women aged 50–51
years at the first screening when projected forward to the 10th
screening was 20.39% (95% CI 20.02–20.76) and 1.76% (95%
CI 1.66–1.87), respectively. Figures 1 and 2 show the estimated
cumulative risk for women aged 50–51 years, with the highest
and lowest risk profiles. The cumulative risk after 10
consecutive rounds in high-risk women was estimated at
51.43% (95% CI 51.02–51.84), while women without these risk
factors had an estimated risk of 7.47% (95% CI 7.23–7.72)
(Figure 1). The differential risk between the highest and the
lowest risk profiles was 43.96%. Protocol characteristics
explained 54.2% of this differential risk, while women’s
personal characteristics explained the remaining 45.8%. The
cumulative risk of a false-positive result for invasive procedures
in high-risk women was 12.02% (95% CI 11.75–12.30) while
that in the lowest risk group was 1.58% (95% CI 1.48–1.69)
(Figure 2). The differential risk between the highest and the
lowest risk profiles was 10.44%. Women’s personal
characteristics explained 73.3% of this differential risk.
discussion
Estimation of the cumulative risk of a false positive aims to
provide the maximum available information to women invited
to participate in breast cancer screening. Nowadays, false-
positive results are a noteworthy adverse effect of screening. If
mortality reduction as a benefit of screening is analyzed in
terms of a sequence of multiple screening participations,
adverse effects should be studied in a similar way.
We estimated that one in every five women who participated
in 10 screening rounds had a false-positive result. These results
are consistent with findings in Norway [7] and the UK [20],
where screening programs’ organization is similar, but are
much lower than the 49.1% observed in the United States [6,
10]. These differences were also observed in a comparison
between the United States and the UK [20]. An explanation for
these findings could be that breast cancer screening in the
United States is not government sponsored and organized,
whereas in Europe programs must meet quality standards
involving lower false-positive rates [14,20–22].
Importantly, the cumulative risk of a false-positive result
involving a biopsy or other invasive procedures was 10-fold or
less lower than for any procedure. Despite its lower risk, the
adverse effect of a false-positive result leading to an invasive
procedure is higher in terms of the physical impact to women
and involves a higher cost than imaging procedures and a delay
in informing women of the results.
Previous studies have found a higher cumulative risk of a false-
positive result leading to invasive procedures [7, 20] in the European
context and an even higher risk in the United States [6, 20].
However, further studies are required to analyze the variability
found in the estimated cumulative risk within the European context.
Several factors have previously been described as influencing
the false-positive recall rate, including the reading method, the
number of mammographic views, mammogram quality and the
radiologist experience [23–25]. In line with the results of several
previous studies [21, 26, 27] we found that double reading was
associated with a higher recall rate (OR = 2.06) and a higher
Table 2. False positives and cancer detection outcomes (by screening mammogram)
Outcome First screening Subsequent screening Overall
n Percentage (95% CI) n Percentage (95% CI) n Percentage (95% CI)
False positive 134 757 8.6 (8.56–8.65) 130 044 4.10 (4.08–4.12) 264 801 5.59 (5.57–5.61)
False positive (invasive) 15 894 1.02 (1.00–1.03) 8542 0.27 (0.26–0.28) 24 436 0.52 (0.51–0.52)
Cancer detection 7065 0.45 (0.44–0.46) 9464 0.30 (0.29–0.30) 16 529 0.35 (0.34–0.35)
CI, confidence interval.
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cancer detection rate (OR = 1.08) than single reading.
However, there is a wide variability in the balance found in
previous studies between the risk and the benefits of double
reading over single reading [11, 14, 21, 22].
Some studies have reported that the increase in recall rate
associated with double reading was reduced when consensus or
arbitration was used over non-consensus double reading [11, 12,
28]. In our study, although the use of consensus and arbitration
did not constitute study variables, 84.8% of double readings
involved consensus or arbitration, while only 15.2% were double
readings without consensus.
Although the European guidelines recommend two views, in
our study some radiology units carried out one view, mainly for
first screening. Our results are in agreement with those of
previous studies that the use of two views reduces the false-
positive risk for all procedures [14], but we also found that the
use of two views increased the false-positive risk for invasive
procedures. We observed a higher detection rate and a lower risk
of false-positive results with digital mammography. A higher
detection rate in younger women has been previously described
[29, 30], while a reduction in overall false-positive rates has been
found in some studies [13, 31] but not in others [32].
Table 3. False-positive risk and cancer detection by screening-protocol characteristics (N = 4 739 498)
Screening mammograms Multivariate analysis (OR, 95% CI)a
False-positive risk (all
procedures)
False-positive risk (invasive
procedures)
Cancer detection
Reading method
Single reading 1 734 930 Ref. Ref. Ref.
Double reading 3 004 568 2.06 (2.00–2.13)b 4.44 (4.08–4.84)b 1.08 (1.04–1.12)b
Number of views
One 1 482 503 Ref. Ref. Ref.
Two 3 256 995 0.77 (0.76–0.79)b 1.56 (1.48–1.64)b 1.02 (0.97–1.06)
Mammography type
Film-screen 4 676 138 Ref. Ref. Ref.
Digital 63 360 0.96 (0.92–1.01) 0.83 (0.72–0.96)b 1.26 (1.10–1.45)b
aMultivariate analysis adjusted by women’s screening number, radiology unit (random effect), screening period and age.
bSignificant at the 95% CI.
OR, odds ratio; CI, confidence interval.
Table 4. False-positive risk and cancer detection by women’s characteristics (adjusted by screening-protocol characteristics) (N = 2 777 429)
Screening mammograms Multivariate analysis (OR, 95% CI)a
False-positive risk (all
procedures)
False-positive risk (invasive
procedures)
Cancer detection
Age at screening (years)
44–49 469 047 1.50 (1.46–1.54)b 1.44 (1.30–1.58)b 0.39 (0.35–0.43)b
50–54 699 256 1.26 (1.23–1.29)b 1.26 (1.15–1.37)b 0.48 (0.44–0.52)b
55–59 695 921 1.13 (1.10–1.16) 1.06 (0.97–1.16) 0.67 (0.62–0.73)b
60–64 633 845 1.06 (1.03–1.09) 0.96 (0.88–1.06) 0.84 (0.77–0.90)b
65–69 279 360 Ref. Ref. Ref.
HRT
No 2 485 550 Ref. Ref. Ref.
Yes 291 879 1.03 (1.01–1.05)b 0.84 (0.78–0.90)b 0.86 (0.80–0.94)b
Menopause
Menopausal 2 157 627 Ref. Ref. Ref.
Premenopausal 619 802 1.31 (1.29–1.33)b 1.22 (1.16–1.29)b 1.16 (1.07–1.25)b
Previous invasive procedure
No 2 585 871 Ref. Ref. Ref.
Yes 191 558 1.52 (1.49–1.56)b 2.00 (1.89–2.12)b 1.31 (1.20–1.42)b
Familial breast cancer
No 2 581 981 Ref. Ref. Ref.
Yes 195 448 1.18 (1.15–1.20)b 1.21 (1.13–1.30)b 1.66 (1.55–1.79)b
Menopause: pre-/perimenopausal or menopausal status; previous invasive procedure: personal previous invasive procedure; familial breast cancer: first-
degree familial history of breast cancer previously described.
aMultivariate analysis adjusted by women’s screening number, screening period, radiology unit (random effect) and reading-protocol variables (reading
method, number of views, mammography type).
bSignificant at the 95% CI.
OR, odds ratio; CI, confidence interval; HRT, hormone replacement therapy.
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Our results on the influence of women’s characteristics are in
agreement with those of previous studies. The risk of a false-
positive result is higher in younger women, adjusted by
screening round, which probably reflects certain age-related
features such as breast density, which we could not study
because information on this factor is not routinely collected.
HRT use was not associated with a higher false-positive risk,
which seems contradictory given the relationship of this
treatment with breast density and breast cancer. However, this
finding might be explained by the lower use of the combination
of estrogens plus progestin, which is associated with breast
density [33, 34], in Spain compared with current
recommendations in other European countries [35]. As
expected, previous invasive procedures and familial breast
cancer were also risk factors both for false-positive risk for all
procedures and false-positive risk for invasive procedures.
A wide range was observed in the estimated cumulative risk
of a false-positive result among the different risk profiles
Figure 1. Cumulative risk and hazard risk of a false-positive result for any procedure for women starting screening at age 50–51 years. Highest risk (double
reading, one view, film-screen mammography, premenopausal status, previous invasive procedures, and familial breast cancer) versus lowest risk profiles
(opposite categories).
Figure 2. Cumulative risk and hazard risk of a false-positive result for invasive procedures for women starting screening at age 50–51 years. Highest risk
(double reading, two views, not using HRT, premenopausal status, previous invasive procedures, and familial breast cancer) versus lowest risk profiles
(opposite categories). HRT, hormone replacement therapy.
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defined, based on women’s personal and protocol-related
characteristics. The false-positive risk over 10 screening rounds
for the highest and the lowest risk profiles ranged from 51.4%
to 7.5% (maximum–minimum ratio: 6.8). The reading-
protocol variables were responsible for over half of the risk
range between the highest and the lowest risk profiles. A similar
proportion in the range (1.58% to 12.0%) was observed for
invasive procedures (ratio: 7.6). The lowest risk value obtained
(1.58%) was close to the estimated baseline risk (1.76%) due to
the small impact of the protective factors obtained from the
regression models. Women’s characteristics played a major role
and explained 73.3% of this variability. Obviously, women’s
personal factors, except HRT use, are unmodifiable, but
evaluating its impact provides essential information about the
risk–benefit balance of breast cancer screening.
This study has some limitations. The information on women’s
personal variables was not always available or complete in all the
radiology units. Although the age distribution between missing
and non-missing data related to women’s variables was similar,
we found a moderately lower false-positive risk for all procedures
and a moderately higher false-positive risk for invasive
procedures in missing data. We analyzed a subsample with the
maximum available information, which allowed us to control for
reading-protocol and women’s characteristics together.
Information on radiologist experience inside and outside the
program could not be obtained. The European guidelines
recommend that radiologists read at least 5000 mammograms/
year and most of the radiologists reading within the screening
program achieved this volume.
In conclusion, our study uses information from a screening
program with distinct screening protocols and at different
stages of development and experience, this being one of the
largest cohorts of screened women ever analyzed. We found
that the screening-protocol and women’s characteristics
strongly affected the cumulative risk of a false positive for all
procedures and for invasive procedures after 10 screening
mammograms. Understanding the sources of variability may
lead to more effective screening programs. The adverse effects
of cancer screening could be reduced by taking modifiable
variables into account when the risks and benefits of screening
are analyzed and more accurate information could be provided
to participating women.
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